The company has developed several proprietary immuno-oncology therapeutic platforms, including TriTETM, CCNKTM, and CCMφTM. The pipeline antibodies developed based on these platforms could stimulate or modulate immune cells to fight against cancer.
CytoCares is a pioneer in utilizing of “Two-Signal” system of T cell activation in the multi-specific antibody design and has expanded its expertise from hematologic malignancies to solid tumor.
Trispecific T-cell Engager (TriTE) offering full activation signal to T cell through co-engagement of TCR/CD3 and co-stimulatory receptor
NK activation receptor agonists or inhibitory receptor antagonists for effective tumor killing
Marcrophage revitalize agents to enhance innate as well as adaptive immunity for cancer treatment
2024年8月11日，惠和生物申报的1类新药CC312冻干粉针剂获批临床，适应症为自身免疫疾病系统性红斑狼疮（SLE）。
2024年6月3日，惠和生物在自免疾病领域的IND申请已正式获得国家药品监督管理局药品审评中心（CDE）受理！
2024年5月24日下午，惠和生物组织的闭门学术研讨沙龙成功举办，与会嘉宾们围绕着“细胞免疫、新药与临床转化”的主题进行分享、讨论和交流。
